1.Application of the Kirkpatrick Four Levels in assessing the training effect for junior nurses from internal medical departments
Miaoqin WANG ; Lin SU ; Airu WANG
Chinese Journal of Practical Nursing 2016;32(2):90-93
Objective To analyze the training effect for junior nurses from internal medical departments of our hospital.Methods Data gathering tool,based on the Kirkpatrick Four Levels,was formulated by means of theoretical research and expert consultation.Before training,investigation of needs was conducted and then training contents were organized.Objective structured clinical examination (OSCE) was implemented before and after the training to obtain information about nurses' comprehensive abilities and to compare with their self-assessed data.Twelve months after the training,the training effect was kept track on from those subjects' head nurses.Results After the training,80 subjects' comprehensive abilities obtained from OSCE scored higher than before the training,(71.51±0.49) vs.(61.92±0.55),t=4.961,P < 0.01.Their selfassessed comprehensive abilities also scored higher than that before,(83.49±0.75) vs.(72.73 ±0.43),t=7.020,P < 0.01,the differences were both statistically significant.By questionnaire training,26 head nurses (26/32,88.46%) in general medical department showed positive assessment over training effect.Nurse's behaviors had improved significantly.In 80 training nurses,60 (75.00%) had become the examples of their colleagues.In 80 patients and their family members,73 cases showed their satisfaction and the satisfaction degree was higher than 90%.Conclusions The Kirkpatrick Four Levels can be applied to assess the training effect for junior nurses and the training mode can effectively improve comprehensive abilities of junior nurses.
2.Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.
Haiyan YAN ; Jing SUN ; Kun WANG ; Huiqiang WANG ; Shuo WU ; Linlin BAO ; Weiqing HE ; Dong WANG ; Airu ZHU ; Tian ZHANG ; Rongmei GAO ; Biao DONG ; Jianrui LI ; Lu YANG ; Ming ZHONG ; Qi LV ; Feifei QIN ; Zhen ZHUANG ; Xiaofang HUANG ; Xinyi YANG ; Yuhuan LI ; Yongsheng CHE ; Jiandong JIANG
Acta Pharmaceutica Sinica B 2021;11(9):2850-2858
COVID-19 pandemic caused by SARS-CoV-2 infection severely threatens global health and economic development. No effective antiviral drug is currently available to treat COVID-19 and any other human coronavirus infections. We report herein that a macrolide antibiotic, carrimycin, potently inhibited the cytopathic effects (CPE) and reduced the levels of viral protein and RNA in multiple cell types infected by human coronavirus 229E, OC43, and SARS-CoV-2. Time-of-addition and pseudotype virus infection studies indicated that carrimycin inhibited one or multiple post-entry replication events of human coronavirus infection. In support of this notion, metabolic labelling studies showed that carrimycin significantly inhibited the synthesis of viral RNA. Our studies thus strongly suggest that carrimycin is an antiviral agent against a broad-spectrum of human coronaviruses and its therapeutic efficacy to COVID-19 is currently under clinical investigation.
3.Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients.
Jiangping HE ; Shuijiang CAI ; Huijian FENG ; Baomei CAI ; Lihui LIN ; Yuanbang MAI ; Yinqiang FAN ; Airu ZHU ; Huang HUANG ; Junjie SHI ; Dingxin LI ; Yuanjie WEI ; Yueping LI ; Yingying ZHAO ; Yuejun PAN ; He LIU ; Xiaoneng MO ; Xi HE ; Shangtao CAO ; FengYu HU ; Jincun ZHAO ; Jie WANG ; Nanshan ZHONG ; Xinwen CHEN ; Xilong DENG ; Jiekai CHEN
Protein & Cell 2020;11(9):680-687